It is estimated over 100,000 people have been treated with Huperzine A in China where it is used as a treatment for Alzheimer’s disease (AD), as well as other kinds of dementia. In addition to being safer than current drugs used to treat AD, it appears more effective in a number of areas. Huperzine A is a compound that can be manufactured in the lab or extracted from club moss extract (Huperzia serrata; qian ceng ta), which has been traditionally used to treat fever and inflammation. Research carried out at the Shanghai Institute of Materia Medica, Huperzine A improved memory significantly better than tacrine or the drug E2020 (Neuroreport 1996, Dec 20: 8 (1): 97-101).
Fifty patients with (AD) were administered 200mcg Huperzine A BID for 8 weeks. Twenty-nine out of fifty patients showed improvements in memory, cognitive, and behavioral functions on the basis of the Wechseler memory scale, Hasegawa dementia scale, and other internationally accepted standards. (Chung Kuo Yao Li hsueh pao 1995, Sept; 16 (5) 391-395)
Huperzine A may reduce injury to cells from strokes, epilepsy, and other disorders. It is being clinically used for treatment of myasthenia gravis in China. It is also being studied in Israel for its ability to be used prophylactically against nerve gas poisoning.
Vinpocetine is derived from the periwinkle plant. It has been used for more than 20 years as a treatment of cerebrovascular disorders. Laboratory experiments indicate that it dilates blood vessels, improves circulation to the brain, improves oxygen utilization, increases glucose metabolism in the brain, and inhibits platelet aggregation. Vinpocetine has been shown to alter properties of the blood to improve blood flow through the brain. It also improves energy available to the brain by inhibiting phosphodiesterase thus preserving ATP, the source of cell energy.
Health Concerns vinpocetine has been featured in over 150 studies. Over thirty quality control tests are conducted for safety and potency. In a study of 203 patients with mild to moderate dementia at the University of Surrey, in England, were administered vinpocetine at doses of 10mg TID or 20mg TID for sixteen weeks. There was a significant cognitive improvement when compared with a placebo. In another double blind trial, vinpocetine produced significant improvement to elderly patients with chronic cerebral dysfunction at dosages of 10mg TID for 30 days, followed by 5mg TID for 60 days.
Known as the “herb of remembrance,” rosemary has been traditionally used to treat digestive disorders, arthritis and headaches. In the past few decades, it has been discovered that rosemary has unique antioxidant properties as well as antimutagenic effects. It is also a Cox-2 inhibitor. Health Concerns rosemary is extracted from rosemary using a unique process that separates the rosemary oil from the herb.
These statements have not been evaluated by the Food and Drug Administration (FDA). These products are not meant to diagnose, treat or cure any disease or medical condition. Please consult your doctor before starting any exercise or nutritional supplement program or before using these or any product during pregnancy or if you have a serious condition.